Cargando…
Novel 3,4-Dihydroisocoumarins Inhibit Human P-gp and BCRP in Multidrug Resistant Tumors and Demonstrate Substrate Inhibition of Yeast Pdr5
Multidrug resistance (MDR) in tumors and pathogens remains a major problem in the efficacious treatment of patients by reduction of therapy options and subsequent treatment failure. Various mechanisms are described to be involved in the development of MDR with overexpression of ATP-binding cassette...
Autores principales: | Sachs, Julia, Döhl, Katja, Weber, Anja, Bonus, Michele, Ehlers, Ferdinand, Fleischer, Edmond, Klinger, Anette, Gohlke, Holger, Pietruszka, Jörg, Schmitt, Lutz, Teusch, Nicole |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6476959/ https://www.ncbi.nlm.nih.gov/pubmed/31040786 http://dx.doi.org/10.3389/fphar.2019.00400 |
Ejemplares similares
-
Dual Inhibition of P-gp and BCRP Improves Oral Topotecan Bioavailability in Rodents
por: Lee, Jaeok, et al.
Publicado: (2021) -
Recent advances in the search of BCRP- and dual P-gp/BCRP-based multidrug resistance modulators
por: Dei, Silvia, et al.
Publicado: (2019) -
Dihydroisocoumarins from Radix Glycyrrhizae
por: Zhao, Songsong, et al.
Publicado: (2018) -
Selectivity profiling of BCRP versus P-gp inhibition: from automated collection of polypharmacology data to multi-label learning
por: Montanari, Floriane, et al.
Publicado: (2016) -
New Substituted Isocoumarins and Dihydroisocoumarins and their Cytotoxic Activities
por: Hampl, Veronika, et al.
Publicado: (2011)